Showing results (21-30 of 74) with videos related to

Sort By:
Pageof 8
American Heart Journal|October 8, 2013
Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failureKim Fox, Ian Ford, Philippe Gabriel Steg, et al.
European Heart Journal|December 28, 2020
Management of refractory angina: an updateAllan Davies, Kim Fox, Alfredo R Galassi, et al.
Circulation. Cardiovascular Quality and Outcomes|December 24, 2015
Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life SubstudyMichal Tendera, Olivier Chassany, Roberto Ferrari, et al.
Cardiology|August 1, 2012
Cardiac rehabilitation to improve physical functioning in refractory angina: a pilot studyElizabeth A Asbury, Carolyn M Webb, Heather Probert, et al.
American Heart Journal|February 17, 2019
A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline characteristicsRoberto Ferrari, Ian Ford, Kim Fox, et al.
International Journal of Cardiology|May 15, 2007
Differences in presentation and management of stable angina from East to West in Europe: a comparison between Poland and the UKCaroline Ann Daly, Janina Stepinska, Tomasz Deptuch, et al.
European Heart Journal|August 25, 2011
Relationship between discharge heart rate and mortality in patients after acute myocardial infarction treated with primary percutaneous coronary interventionM Louisa Antoni, Helèn Boden, Victoria Delgado, et al.
International Journal of Cardiology|January 9, 2015
Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysisJasper J Brugts, Laura van Vark, Martijn Akkerhuis, et al.
Lancet (London, England)|September 3, 2020
Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trialRoberto Ferrari, Ian Ford, Kim Fox, et al.
The American Journal of Cardiology|January 21, 2011
Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy)Michal Tendera, Mario Talajic, Michele Robertson, et al.
Pageof 8